About Enterra Medical
Our company’s mission
Enterra Medical is dedicated to a singular focus of helping more people with gastroparesis live better lives by advancing technology, expanding clinical science, and accelerating access to Enterra® Therapy.
Raising the standard of relief
Enterra Medical was formed in 2022 to help more people living with gastroparesis find meaningful relief through Enterra Therapy—a device approved by the U.S. Food and Drug Administration in 2000 under a Humanitarian Device Exception.
Enterra Medical operates with a clear vision: to raise the standard of relief for gastroparesis chronic nausea and vomiting by shaping the future of gastric electrical stimulation.
We are guided by a deep commitment to the people living with these life-changing symptoms—and to the clinicians who care for them. Through substantial investments in research and development, spearheading landmark clinical trials, offering critical clinical education, and expanding access to gastric electrical stimulation, Enterra Medical seeks to offer hope and help for patients who wish to take back their seat at the table.
IMPORTANT SAFETY INFORMATION
Enterra Therapy for treatment of chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.
HUMANITARIAN DEVICE
Authorized by Federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated. What does this mean?